On June 11, 2024, Voyager Therapeutics, Inc. (the Company) and Nathan Jorgensen entered into an employment agreement (the Jorgensen Agreement), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024 (the Jorgensen Commencement Date). On June 5, 2024, the board of directors of the Company authorized and approved the appointment of Dr. Jorgensen as principal financial officer, and principal accounting officer of the Company, effective upon the Jorgensen Commencement Date, and the compensation committee of the Board (the Compensation Committee) authorized and approved the compensation arrangements for Dr. Jorgensen. Robin Swartz will continue to serve as the Company?s Chief Operating Officer.

Dr. Jorgensen, age 47, previously served as Chief Financial Officer of Vor Biopharma Inc., a biotechnology company, from May 2020 to June 2024. Prior to joining Vor Biopharma, Dr. Jorgensen served as Healthcare Portfolio Senior Manager for the Qatar Investment Authority from August 2016 to April 2020. Previously, Dr. Jorgensen served as Senior Research Analyst at Calamos Investments LLC, Associate Research Analyst at Stifel, Nicolaus & Company, Incorporated, and Competitive Intelligence Senior Analyst at Prescient Healthcare Group.

Prior to entering the financial sector, Dr. Jorgensen investigated the pathobiology of Parkinson?s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his Ph.D. in neuroscience from the University of Minnesota, his M.B.A. from the Cornell SC Johnson College of Business, and his B.A. from St. John?s University.